Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model-Reference-Cited by-同舟云学术

Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model

Published:2009-06-09 Issue:23 Volume:52 Page:7364-7367
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Yue Eddy W.¹,Douty Brent¹,Wayland Brian¹,Bower Michael¹,Liu Xiangdong¹,Leffet Lynn¹,Wang Qian¹,Bowman Kevin J.¹,Hansbury Michael J.¹,Liu Changnian¹,Wei Min¹,Li Yanlong¹,Wynn Richard¹,Burn Timothy C.¹,Koblish Holly K.¹,Fridman Jordan S.¹,Metcalf Brian¹,Scherle Peggy A.¹,Combs Andrew P.¹

Affiliation:

1. Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm900518f

Reference23 articles.

1. Indoleamine 2,3-dioxygenase and tumor-induced tolerance

2. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism

3. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells